tbuckley/cabot-search huggingface dataset:
Review: Antioxidant vitamin or mineral supplements do not prevent age-related macular degeneration
Authors: Lorraine Macdonald
Journal: Annals of Internal Medicine (2017)

ACP Journal Club21 November 2017Review: Antioxidant vitamin or mineral supplements do not prevent age-related macular degenerationLorraine Macdonald, MD, MSC, FRCP (C)Lorraine Macdonald, MD, MSC, FRCP (C)Tennessee Department of Health, Nashville, Tennessee, USA (L.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-167-10-056 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationEvans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev. 2017;7:CD000253. https://pubmed.ncbi.nlm.nih.gov/28756617Clinical Impact RatingsGIM/FP/GP: Geriatrics: References1 Rosenberg T, Klie F. The incidence of registered blindness caused by age-related macular degeneration. Acta Ophthalmol Scand. 1996;74:399-402. [PMID: 8883559] Google Scholar2 Mares JA, Voland RP, Sondel SA, et al. Healthy lifestyles related to subsequent prevalence of age-related macular degeneration. Arch Ophthalmol. 2011;129:470-80. [PMID: 21149749] Google Scholar3 Sui GY, Liu GC, Liu GY, et al. Is sunlight exposure a risk factor for age-related macular degeneration? A systematic review and meta-analysis. Br J Ophthalmol. 2013;97:389-94. [PMID: 23143904] Google Scholar Author, Article, and Disclosure InformationAffiliations: Tennessee Department of Health, Nashville, Tennessee, USA (L.M.)This article was published at Annals.org on 7 November 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoReview: In age-related macular degeneration, antioxidant multivitamins and zinc supplements each decrease progression Lorraine Macdonald Review: In age-related macular degeneration, antioxidant multivitamins and zinc supplements each decrease progression Lorraine Macdonald Metrics Cited byRhizoma Paridis total saponins alleviate H2O2‑induced oxidative stress injury by upregulating the Nrf2 pathway 21 November 2017Volume 167, Issue 10Page: JC56KeywordsHealth careMacular degenerationNeovascularizationObservational studiesRisk ratioVisionVitamin CVitamin EZinc ePublished: 21 November 2017 Issue Published: 21 November 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract 15375: Ventilation is Associated With Increased Survival During 30:2 Cardiopulmonary Resuscitation (CPR)
Authors: Mary P Chang, Yuanzheng Lu, Elisabete Aramendi, Ahamed H Idris
Journal: Circulation (2017)

Introduction: Recent studies have confirmed the association of survival with high quality chest compressions during early CPR. However, evidence is limited regarding ventilation during early CPR an...
Abstract 15083: Substitution of Adult Cardiac Troponin I, cTnI, With the Fetal Isoform, ssTnI, in Adult Mice Augments Metabolic Remodeling and Reduces Both Decompensatory Hypertrophy and Contractile Dysfunction During Chronic Pressure Overload
Authors: Andrew N Carley, Domenico M Taglieri, Jian Bi, R. John Solaro, E. Douglas Lewandowski
Journal: Circulation (2013)

The fetal heart is primarily dependent on glycolysis, but following birth switches to oxidative, long chain fatty acid (LCFA)-dependent metabolism. Adult hearts under pathological stress revert to a fetal metabolic profile. Paralleling metabolic development is the replacement of the fetal isoform of the contractile protein, troponin I (slow skeletal- or ssTnI) by adult cardiac isoform (cTnI). Interestingly, troponin does not revert to its fetal isoform in response to stress unlike other contractile proteins. We previously found adult transgenic mouse hearts expressing ssTnI, to be protected from ischemia by increased glycolytic flux. Since pressure overload induces a fetal metabolic profile, we investigated the response of adult mouse hearts expressing ssTnI to transverse aortic constriction (TAC) for comparison to sham operated mice (Sham).  Transgenic, ssTnI expressing mice and nontransgenic (NTG) littermates (2-3 mos) underwent TAC. At 10 weeks, TAC induced a 25% increase in NTG heart weight:tibila length but only a 7% increase in ssTnI hearts (P  Expression of a single fetal myofilament protein into adulthood in the ssTnI mouse heart confers protection against cardiac decompensation due to pressure overload by inducing an enhanced metabolic remodeling with preserved energetics.
Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications
Authors: Cláudia Martins, Flávia Sousa, Francisca Araújo, Bruno Sarmento
Journal: Advanced Healthcare Materials (2017)

Abstract Poly(lactic‐ co ‐glycolic) acid (PLGA) is one of the most versatile biomedical polymers, already approved by regulatory authorities to be used in human research and clinics. Due to its valuable characteristics, PLGA can be tailored to acquire desirable features for control bioactive payload or scaffold matrix. Moreover, its chemical modification with other polymers or bioconjugation with molecules may render PLGA with functional properties that make it the Holy Grail among the synthetic polymers to be applied in the biomedical field. In this review, the physical–chemical properties of PLGA, its synthesis, degradation, and conjugation with other polymers or molecules are revised in detail, as well as its applications in drug delivery and regeneration fields. A particular focus is given to successful examples of products already on the market or at the late stages of trials, reinforcing the potential of this polymer in the biomedical field.
Understand the cogs to understand cognition
Authors: Adam H Marblestone, Greg Wayne, Konrad P Kording
Journal: Behavioral and Brain Sciences (2017)

Abstract Lake et al. suggest that current AI systems lack the inductive biases that enable human learning. However, Lake et al.'s proposed biases may not directly map onto mechanisms in the developing brain. A convergence of fields may soon create a correspondence between biological neural circuits and optimization in structured architectures, allowing us to systematically dissect how brains learn.
The logic of syntactic priming and acceptability judgments
Authors: Phoebe Gaston, Nick Huang, Colin Phillips
Journal: Behavioral and Brain Sciences (2017)

Abstract A critical flaw in Branigan &amp; Pickering's (B&amp;P's) advocacy of structural priming is the absence of a theory of priming. This undermines their claims about the value of priming as a methodology. In contrast, acceptability judgments enable clearer inferences about structure. It is important to engage thoroughly with the logic behind different structural diagnostics.
P2.07-045 A Retrospective Analysis of Nivolumab-Related Pneumonitis in Non-Small Cell Lung Cancer Patients
Authors: S. Tsujino, T. Ikeda, H. Taniguchi, M. Shimada, H. Gyoutoku, H. Senju, H. Yamaguchi, K. Nakatomi, M. Fukuda, H. Mukae
Journal: Journal of Thoracic Oncology (2017)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Authors: Sara A Hurvitz, Miguel Martin, W Fraser Symmans, Kyung Hae Jung, Chiun-Sheng Huang, Alastair M Thompson, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Mario Campone, Jean-François Boileau, Matthias W Beckmann, Karen Afenjar, Rodrigo Fresco, Hans-Joachim Helms, Jin Xu, Yvonne G Lin, Joseph Sparano, Dennis Slamon
Journal: The Lancet Oncology (2017)
Proteases and protease inhibitors in infectious diseases
Authors: Ayodeji A. Agbowuro, Wilhelmina M. Huston, Allan B. Gamble, Joel D. A. Tyndall
Journal: Medicinal Research Reviews (2017)

Abstract There are numerous proteases of pathogenic organisms that are currently targeted for therapeutic intervention along with many that are seen as potential drug targets. This review discusses the chemical and biological makeup of some key druggable proteases expressed by the five major classes of disease causing agents, namely bacteria, viruses, fungi, eukaryotes, and prions. While a few of these enzymes including HIV protease and HCV NS3‐4A protease have been targeted to a clinically useful level, a number are yet to yield any clinical outcomes in terms of antimicrobial therapy. A significant aspect of this review discusses the chemical and pharmacological characteristics of inhibitors of the various proteases discussed. A total of 25 inhibitors have been considered potent and safe enough to be trialed in humans and are at different levels of clinical application. We assess the mechanism of action and clinical performance of the protease inhibitors against infectious agents with their developmental strategies and look to the next frontiers in the use of protease inhibitors as anti‐infective agents.
Validated nCounter platform to stratify colorectal cancer (CRC) into Consensus Molecular Subtypes (CMS) and CRCassigner subtypes in Asian population
Authors: E. Fontana, C. Ragulan, K. Eason, K. Si-Lin, T.W. Siew, G. Nyamundanda, Y. Patil, P. Poudel, I. Chau, I.B. Tan, A. Sadanandam
Journal: Annals of Oncology (2017)
Romosozumab Prevents Fractures in Women With Osteoporosis
Authors: Anita Slomski
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incremental Value of Deformation Imaging and Hemodynamics Following Heart Transplantation
Authors: Yukari Kobayashi, Naga Lakshmi Sudini, June-Wha Rhee, Marie Aymami, Kegan J Moneghetti, Sara Bouajila, Yuhei Kobayashi, Juyong B Kim, Ingela Schnittger, Jeffery J Teuteberg, Kiran K Khush, William F Fearon, Francois Haddad
Journal: JACC Heart Failure (2017)
Patients and animal models of CNGβ1-deficient retinitis pigmentosa support gene augmentation approach
Authors: Simon M. Petersen-Jones, Laurence M. Occelli, Paige A. Winkler, Winston Lee, Janet R. Sparrow, Mai Tsukikawa, Sanford L. Boye, Vince Chiodo, Jenina E. Capasso, Elvir Becirovic, Christian Schön, Mathias W. Seeliger, Alex V. Levin, Stylianos Michalakis, William W. Hauswirth, Stephen H. Tsang
Journal: Journal of Clinical Investigation (2017)

Retinitis pigmentosa (RP) is a major cause of blindness that affects 1.5 million people worldwide. Mutations in cyclic nucleotide-gated channel β 1 (CNGB1) cause approximately 4% of autosomal recessive RP. Gene augmentation therapy shows promise for treating inherited retinal degenerations; however, relevant animal models and biomarkers of progression in patients with RP are needed to assess therapeutic outcomes. Here, we evaluated RP patients with CNGB1 mutations for potential biomarkers of progression and compared human phenotypes with those of mouse and dog models of the disease. Additionally, we used gene augmentation therapy in a CNGβ1-deficient dog model to evaluate potential translation to patients. CNGB1-deficient RP patients and mouse and dog models had a similar phenotype characterized by early loss of rod function and slow rod photoreceptor loss with a secondary decline in cone function. Advanced imaging showed promise for evaluating RP progression in human patients, and gene augmentation using adeno-associated virus vectors robustly sustained the rescue of rod function and preserved retinal structure in the dog model. Together, our results reveal an early loss of rod function in CNGB1-deficient patients and a wide window for therapeutic intervention. Moreover, the identification of potential biomarkers of outcome measures, availability of relevant animal models, and robust functional rescue from gene augmentation therapy support future work to move CNGB1-RP therapies toward clinical trials.
Time trends in major hepatic complications in primary biliary cholangitis : incidence and transplant-free survival
Authors: Maren H Harms, Willem J Lammers, Douglas Thorburn, Christophe Corpechot, Pietro Invernizzi, Harry L Janssen, Pier Maria Battezzati, Frederik Nevens, Keith D Lindor, Annarosa Floreani, Cyriel Y Ponsioen, Marlyn J Mayo, George N Dalekos, Tony Bruns, Albert Pares, Andrew Mason, Xavier Verhelst, Kris Kowdley, Jorn C Goet, Gideon M Hirschfield, Bettina E Hansen, Henk R van Buuren
Journal: Hepatology (2017)
Association of Coded Severity With Readmission Reduction After the Hospital Readmissions Reduction Program
Authors: Andrew M. Ibrahim, Justin B. Dimick, Shashank S. Sinha, John M. Hollingsworth, Ushapoorna Nuliyalu, Andrew M. Ryan
Journal: JAMA Internal Medicine (2017)

This study uses the Medicare Provider Analysis and Review file to examine whether coded severity of illness is associated with reduced rates of readmission after implementation of the Hospital Readmissions Reduction Program.
P3.02a-027 A Retrospective Analysis of the Efficacy and Safety of ALK Inhibitors in ALK-Positive Lung Cancer Patients
Authors: Kazutoshi Komiya, Tomomi Nakamura, Yuki Kurihara, Haruki Hirakawa, Hironori Sadamatsu, Chiho Nakashima, Hitomi Umeguchi, Yuji Takeda, Shinya Kimura, Naoko Sueoka-Aragane
Journal: Journal of Thoracic Oncology (2017)
Programme de formation du personnel des services de santé pour la gestion des maladies hautement infectieuses
Authors: A Baka, F M Fusco, V Puro, N Vetter, P Skinhoj, K Ott, H Siikamäki, H R Brodt, R Gottschalk, P Follin, B Bannister, G De Carli, C Nisii, J Heptonstall, G Ippolito
Journal: Eurosurveillance (2007)

L’epidemie de SRAS, la menace du bioterrorisme et de recents exemples de maladies hautement infectieuses importees en Europe ont tous fait ressortir l’importance d’une gestion adequate de la sante clinique et publique en cas de situation d’urgence face a des maladies infectieuses.
Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice
Authors: Ayana Kon, Satoshi Yamazaki, Yasuhito Nannya, Keisuke Kataoka, Yasunori Ota, Masahiro Marshall Nakagawa, Kenichi Yoshida, Yusuke Shiozawa, Maiko Morita, Tetsuichi Yoshizato, Masashi Sanada, Manabu Nakayama, Haruhiko Koseki, Hiromitsu Nakauchi, Seishi Ogawa
Journal: Blood (2017)
Abstract 13207: Successful Catheter Ablation of Symptomatic Ventricular Arrhythmia After Left Ventricular Assist Device Implantation
Authors: Jens Garbade, Julia Fischer, Sven Lehmann, Anna Meyer, Arash Arya, Gerhard Hindricks, Friedrich-Wilhelm Mohr
Journal: Circulation (2016)

Introduction: Ventricular tachycardia (VT) is a common finding following implantation of a continuous-flow left ventricular assist device (LVAD). We report our experience, technical feasibility and efficacy of endocardial VT-ablation to treat symptomatic patients with LVAD. Hypothesis: Interventional ablation of VT after LVAD implantation can be performed effectively and safely. Methods: A retrospective analysis of all patients supported with a LVAD who were referred for catheter ablation to treat recurrent symptomatic VT was performed. Results: Between January 2012 and August 2014, 159 patients underwent implantation of a LVAD. In eight patients (all of whom had an ICD before LVAD implantation) an ablation was indicated due to recurrent episodes of VT, leading to ICD shock or recurrent hemodynamic instability. A total of 11 ablation procedures were performed. The first ablation was performed after an average of 142 ± 130 days after LVAD implantation. Between the implantation of the LVAD and the first ablation procedure 24 ± 18 appropriate shocks per patient were delivered. For catheter ablation the CARTO 3 mapping system was utilized. Nine clinical VT episodes were able to be induced in four patients. Seven of these VT epsiodes (77.8%) were successfully ablated after activation mapping in these patients. In two patients a monomorphic VT origin was located in the epicardium and could not be ablated successfully, but only in one patient was it inducible at the end of the procedure (12.5%). In six patients voltage mapping was conducted. The low voltage area in four patients extended to the implantation area of the inflow cannula, and of these, all were rendered non-inducible after ablation. All patients remained hemodynamically stable during the procedure. Although the majority had a reduction in VA frequency, in two patients clinical VT recurred, making a second ablation necessary. There were no complications associated with the ablation procedures. The patients were free from ICD shock for an interval of 209 ± 193 days. Conclusions: VT ablation is a feasible, safe and effective treatment option in patients with recurrent triggering of VT episodes leading to ICD shock after implantation of a LVAD.
Abstract 19297: Susceptibility Loci for Clinical CAD Predispose to Subclinical Coronary Atherosclerosis Throughout the Life Course
Authors: Elias Salfati, Shuktika Nandkeolyar, Stephen Fortmann, Stephen Sidney, Mark A Hlakty, Thomas Quertermous, Alan S Go, Carlos Iribarren, Benjamin A Goldstein, Themistocles L Assimes
Journal: Circulation (2014)

Recent genome wide association studies (GWAS) have identified 49 single nucleotide polymorphisms (SNPs) associated with clinically significant complications of CAD including myocardial infarction (MI), CABG, PCI, and/or angina. The mechanism by which these loci influence the risk of clinical CAD remains largely unclear. We hypothesized that variants at these loci collectively facilitate the formation of coronary plaque in a monotonic fashion throughout the life course. We used genetic data from dbGAP (SEA, FHS, and MESA) as well as from the Stanford-Kaiser ADVANCE study imputed to the 1000 genomes project to examine the association between a genetic risk score (GRS) of high-risk alleles at these 49 SNPs and the presence of subclinical atherosclerosis. Subclinical atherosclerosis was identified by either pathologic examination of the coronary arteries or by radiographic assessment of coronary artery calcification (CAC). We stratified white/European subjects within each study into one of five age groups (≤30, 31-45, 46-60, 61-75, &gt;75 years) and defined cases as subjects with either any raised lesions in their right coronary artery on autopsy (SEA, 26.7% subjects aged 18 to 30 years at time of unexpected death) or with an age and sex specific CAC score &gt;75th percentile (all other studies, age &gt; 30 years). Among 1561 cases and 5068 controls, we found a one SD increase in the GRS was associated with a 28% increased risk of having advanced subclinical coronary atherosclerosis (p = 3.82 x 10 -16 ). This increase in risk was significant in every age stratum (.01 &gt; p &gt; 9.4 x 10 -7 ) and was remarkably similar across all age strata (p test of heterogeneity = 0.99). We obtained near identical results and levels of significance when we restricted the GRS to 33 SNPs not associated with traditional risk factors. Our findings strongly support the notion that susceptibility alleles for clinical CAD uncovered through large-scale meta-analysis of GWAS uniformly promote the development of coronary atherosclerosis from birth. This predisposition is sustained at a constant level throughout one’s lifetime. Given it is observed at the earliest stage of plaque formation, it is unlikely to involve a concurrent predisposition to plaque rupture and/or thrombosis.
Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan
Authors: Yutaka Tsukune, Makoto Sasaki, Takeshi Odajima, Kazutaka Sunami, Tomomi Takei, Yukiyoshi Moriuchi, Masaki Iino, Atsushi Isoda, Aya Nakaya, Tsuyoshi Muta, Takaaki Miyake, Koji Miyazaki, Takayuki Shimizu, Kei Nakajima, Aiko Igarashi, Koji Nagafuji, Taro Kurihara, Tomonori Aoyama, Hiroki Sugimori, Norio Komatsu
Journal: Blood Cancer Journal (2017)
Consumer Behaviors Among Individuals Enrolled in High-Deductible Health Plans in the United States
Authors: Jeffrey T. Kullgren, Elizabeth Q. Cliff, Christopher Krenz, Brady T. West, Helen Levy, A. Mark Fendrick, Angela Fagerlin
Journal: JAMA Internal Medicine (2017)

The Price Will Be Right—How to Help Patients and Providers Benefit from the New CMS Transparency Rule
Legionelosis asociada a los viajes en turistas europeos de visita en España: nota del centro coordinador del EWGLI
Authors: C Joseph
Journal: Eurosurveillance (1997)

Este interesante trabajo analiza los datos de casos de legionelosis asociada a viajes a Espana y destaca algunos asuntos relacionados con el sistema de vigilancia del Grupo Europeo de Trabajo para Infecciones por Legionella (EWGLI), como la declaracion de casos con informacion insuficiente, especialmente en los primeros anos cuando comenzo el programa, y la dificultad de interpretar datos cuando la informacion esta incompleta. Se esta llevando a cabo una actualizacion del software de EWGLI a fin de incluir los ultimos avances del programa e incorporar metodos mejorados para efectuar analisis. El nuevo software se distribuira a todos los centros en el transcurso del ano.
Data Sharing from Clinical Trials — A Research Funder’s Perspective
Authors: Robert Kiley, Tony Peatfield, Jennifer Hansen, Fiona Reddington
Journal: New England Journal of Medicine (2017)

Representatives of the Wellcome Trust, the Medical Research Council, Cancer Research UK, and the Bill and Melinda Gates Foundation describe the importance of sharing clinical-trial data for reasons of transparency, good practice, and accelerated dissemination of results.
18F-FDG PET/CT Imaging of Hidradenocarcinoma Arising From Preexisting Hidradenoma of the Knee
Authors: Tirth V. Patel, Jorge Oldan
Journal: Clinical Nuclear Medicine (2017)

Malignant tumors of the sweat glands are exceedingly rare and aggressive tumors. We present here a case of a 60-year-old man with a malignant hidradenocarcinoma that developed in a background of preexisting benign hidradenoma on the lateral aspect of the knee that was initially resected, but rapidly recurred with associated inguinal lymphadenopathy. F-FDG PET/CT was performed as part of preoperative staging, which demonstrated abnormal inguinal lymph nodes and metastatic disease to the lungs. FDG PET/CT can play an invaluable role in the initial staging and follow-up of this rare malignancy.